The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, provides insight into the ReKInDLE study (NCT05896228), a Phase II trial of iberdomide, carfilzomib, daratumumab, and dexamethasone (IberKDd) quadruplet therapy in relapsed/refractory (R/R) multiple myeloma (MM), highlighting an encouraging measurable residual disease (MRD) negativity rate of 71% in evaluable patients who have received one to three prior lines of therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
